Abstract
Piperazine derivatives of 2-furanyl[1,2,4]triazolo[1,5-a][1,3,5]triazine have recently been demonstrated to be potent and selective adenosine A(2a) receptor antagonists with oral activity in rodent models of Parkinson's disease. We have replaced the piperazinyl group with a variety of linear, monocyclic, and bicyclic diamines. Of these diamines, (R)-2-(aminomethyl)pyrrolidine is a particularly potent and selective replacement for the piperazinyl group. With this diamine component, we have been able to prepare numerous analogues with low nanomolar affinity toward the A(2a) receptor and good selectivity with respect to the A(1) receptor (>200-fold in some cases). Selected analogues from this series of [1,2,4]triazolo[1,5-a][1,3,5]triazine have now been shown to be orally active in the mouse catalepsy model.
MeSH terms
-
Adenosine A2 Receptor Antagonists*
-
Administration, Oral
-
Animals
-
Antiparkinson Agents / chemical synthesis*
-
Antiparkinson Agents / chemistry
-
Antiparkinson Agents / pharmacology
-
Binding, Competitive
-
Biological Availability
-
Catalepsy / drug therapy
-
Cerebral Cortex / drug effects
-
Cerebral Cortex / metabolism
-
Combinatorial Chemistry Techniques
-
Diamines / chemical synthesis*
-
Diamines / chemistry
-
Diamines / pharmacology
-
In Vitro Techniques
-
Male
-
Mice
-
Pyrrolidines / chemical synthesis*
-
Pyrrolidines / chemistry
-
Pyrrolidines / pharmacology
-
Radioligand Assay
-
Rats
-
Rats, Sprague-Dawley
-
Stereoisomerism
-
Triazines / chemical synthesis*
-
Triazines / chemistry
-
Triazines / pharmacology
-
Triazoles / chemical synthesis*
-
Triazoles / chemistry
-
Triazoles / pharmacology
Substances
-
Adenosine A2 Receptor Antagonists
-
Antiparkinson Agents
-
Diamines
-
Pyrrolidines
-
Triazines
-
Triazoles